27.07.2011 • NewsLonzaQ2 2011sales and profits

Strong Franc hits Lonza's Profit

Lonza reported Wednesday that its first-half profit fell 28% to 97 million Swiss francs or 1.89 francs per share from 135 million francs or 2.61 francs a year ago.

Core profit, which excluded items, dropped 23% to 107 million francs or 2.08 francs per share.

For the first half, sales fell 8.3% to 1.19 billion francs from 1.30 billion francs last year, due to strong negative currency exchange rate impacts. At constant exchange rate, revenue grew 4.8% with strong performance in Biological Custom Manufacturing and Development Services. Looking ahead, the company said it remains on track to deliver continued growth for the full year, despite ongoing market volatility combined with macro-economic uncertainties.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.